Shanghai Borui Jian Pharmaceutical

Shanghai Borui Jian Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology. The company focuses on the DNA damage response (DDR) pathway, aiming to develop highly selective inhibitors that address unmet medical needs in cancer treatment. Its lead candidate, BRJ-001, is a potent and selective ATR inhibitor currently undergoing Phase 1 clinical trials for patients with advanced solid tumors. Founded in 2019 by Dr. Jian Zhang, the company has secured significant investment from leading venture capital firms, including Qiming Venture Partners and TF Capital. Borui Jian leverages its internal R&D capabilities to advance a pipeline of novel candidates from early discovery through clinical proof-of-concept.